“We found that we can move many of our staff offsite and go to remote workforce options,” says Scott Sellinger, MD.
At the 2021 LUGPA Annual Meeting, Scott Sellinger, MD, moderated the discussion, “Re-imagining Our Independent Urology Practices: What’s the New Normal?” The panel covered how the changes LUGPA facilitated for independent urology practices during the pandemic and what continued
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.